Skip to main content
main-content

28-09-2020 | Gastrointestinal cancer | Video

ESMO 2020 | PFS boost with nivolumab–chemotherapy for advanced gastric, gastro-oesophageal cancer

Narikazu Boku gives an overview of the ATTRACTION-4 data demonstrating improved outcomes with the addition of nivolumab to chemotherapy in the treatment-naïve, advanced or recurrent gastric or gastro-oesophageal junction cancer setting (2:48).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits